> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Doma Perpetual Sold 2,936,794 Pacira Shares And Now Reports Owning None
- URL: https://www.bullished.co/doma-perpetual-sold-2-936-794-pacira-shares-and-now-reports-owning-none-28754ee2/
- Published: 2026-10-13T22:16:17.000Z
- Updated: 2026-10-29T20:22:28.000Z
- Description: An amendment to Doma's Schedule 13D says the group fell below 5% of Pacira on October 8, with sales at $36.29 and $36.34 a share.
- Author: Matteo Parrino
- Tags: SEC Filings, PCRX, Industry: Healthcare, Topic: Ownership & Activism

Doma Perpetual Capital Management and six co-filers now report [0 shares and 0%](https://www.sec.gov/Archives/edgar/data/0001962221/000110465926115589/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Pacira BioSciences](https://www.bullished.co/tag/pcrx/) common stock, according to Amendment No. 4 to their Schedule 13D, the activist-investor ownership disclosure, filed Tuesday. The filing says the group ceased to be a holder of more than five percent of the shares on October 8, 2026.

## What the amendment reports

An [annex to the filing](https://www.sec.gov/Archives/edgar/data/1962221/000110465926115589/tm2627486d1%5Fex99-2.htm?ref=bullished.co) lists four open-market sales totaling 2,936,794 shares. Three came on October 8, all at $36.29 a share, and the last was 10 shares at $36.34 on October 13.

The October 8 sellers were Doma's master fund (1,965,765 shares), The John Templeton Foundation (812,019) and Pedro Escudero personally (159,000). Escudero is the chief executive and chief investment officer of Doma Perpetual Capital Management. The foundation is a discretionary investment management client of Doma, which also manages the master fund.

The seven reporting persons are Doma Perpetual Capital Management, DOMA1, the master fund, Doma Perpetual Partners GP, Escudero, the foundation and DOMA2\. Each shows 0 shares and 0% of the class.

The amendment amends only the identity, ownership and exhibit items. It adds no new demands.

## What it changes

The group no longer reports a stake in Pacira. Amendment No. 4 follows the original Schedule 13D filed August 8, 2025, and amendments filed November 10, 2025, January 2, 2026 and March 12, 2026.

Percentages in the filing are calculated on 39,861,886 shares outstanding as of August 3, 2026, taken from Pacira's quarterly report for the period ended June 30, 2026.

Pacira shares closed at $36.31 on Tuesday and traded at $36.38 in Tuesday after-hours trading, up about 0.19%, according to market data. The company's market value was about $1.5 billion at that close.

The October 13 sale of 10 shares at $36.34 was the last transaction listed in the annex.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — Doma Perpetual Capital Management LLC re: Pacira BioSciences, Inc. (PCRX)](https://www.sec.gov/Archives/edgar/data/0001962221/000110465926115589/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13D/A Exhibit 99.1 — EXHIBIT 99.1](https://www.sec.gov/Archives/edgar/data/1962221/000110465926115589/tm2627486d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13D/A Exhibit 99.2 — EXHIBIT 99.2](https://www.sec.gov/Archives/edgar/data/1962221/000110465926115589/tm2627486d1%5Fex99-2.htm?ref=bullished.co) — SEC EDGAR
- [Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative](https://sg.finance.yahoo.com/news/pacira-biosciences-pcrx-molteni-deal-200829338.html?ref=bullished.co) — Yahoo Finance

### More on Pacira BioSciences

- [Viatris Agrees To Buy Pacira For $36.50 A Share In Cash, A $1.65 Billion Deal With A $62.0 Million Break Fee](https://www.bullished.co/viatris-agrees-to-buy-pacira-for-36-50-a-share-in-cash-a-1-65-billion-deal-with-a-62-0-14d71d09/)

[All Pacira BioSciences (PCRX) coverage →](https://www.bullished.co/tag/pcrx/)